Abstracts tagged "rheumatoid arthritis"

Abstract Number: PP08 • ACR Convergence 2023
Finding Gratitude in Adversity: The Impact of Finding the Right Rheumatologist
Yaideliz Acevedo, Global Healthy Living Foundation, Newark, NJ
Background/Purpose: I recall sitting in the doctor's office with my one-month-old baby in his stroller, hearing the words "You have rheumatoid arthritis." At 21, I…
Abstract Number: 0016 • ACR Convergence 2023
Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: TP53, a tumor-suppressor protein known as the guardian of the genome, plays a critical role in regulating genomic stability and cellular function. When TP53…
Abstract Number: 0079 • ACR Convergence 2023
CD4 T Cell Repertoire Features in RA Patients with High-risk HLA-DRB1 Alleles
Amit Lakhanpal¹, Kazuyoshi Ishigaki², Anvita Singaraju¹, Alejandro Kochen³, Miriam Fein¹, Soumya Raychaudhuri⁴ and Laura Donlin¹, ¹Hospital for Special Surgery, New York, NY, ²RIKEN, Tokyo, Japan, ³Yale School of Medicine, New Haven, CT, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: A role for CD4 T cells in RA pathology is supported by the effectiveness of T cell therapies, genetic studies implicating T cell gene…
Abstract Number: 0217 • ACR Convergence 2023
Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
Tali Eviatar¹, Victoria Furer², Ilana Kaufman³, David levartovsky², Ofir Elalouf², Devy Zisman⁴, Tal Gazitt⁵, Amir Haddad⁴, Muna Elias⁶, Joy Feld⁷, Alexandra Balbir-Gurman⁸, Yolanda Braun Moscovici⁹, Sara Pel¹⁰, sharon Nevo¹¹, Daphna Paran² and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Ramat Gan, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Tel Aviv Medical Center, Petah-Tikva, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Carmel Hospital, Haifa, Israel, ⁶rheumatology unit, Haifa, Israel, ⁷Carmel and Zvulun Medical Centre, Haifa, Israel, ⁸Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ⁹Rambam Heath Care Campus, Haifa, Israel, ¹⁰Tel Aviv Medical Center, Modiin, Israel, ¹¹Tel Aviv Sourasky Medical Center, Givataim, Israel
Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…
Abstract Number: 0383 • ACR Convergence 2023
Identification of Contributing Factors to Difficult-to-Treat Rheumatoid Arthritis (D2T RA) in a Cohort of 972 Patients Using a Natural Language Processing (NLP) Approach
Hugo BERGIER¹, Thibaut Fabacher², Nathanaël Sedmak², Erik Sauleau² and Jacques-Eric Gottenberg³, ¹Hautepierre Hospital, Strasbourg, France, ²Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³Rheumatology Department, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Natural Language Processing (NLP), an interdisciplinary field combining artificial intelligence and language science, has gained significant interest in the medical domain for automated collection…
Abstract Number: 0399 • ACR Convergence 2023
Differential Synovial Tissue Enrichment of Oxylipins and Their Mediators Across Rheumatoid Arthritis Trajectory
Simone Perniola¹, Jessica Murillo-Saich², Barbara Tolusso³, Clara Di Mario³, Marco Gessi⁴, Dario Bruno⁵, Luca Petricca⁶, Maria Rita Gigante⁶, Elisa Gremese⁵, Monica Guma⁷ and Stefano Alivernini⁸, ¹Division of Clinical Immunology – Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Department of Medicine, University of California San Diego, La Jolla, CA, ³Immunology Research Core Facility – Gemelli Science and Technology Park (GSTeP) - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁴Division of Pathology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Division of Rheumatology, Institute of Rheumatology and Affine Sciences, School of Medicine, Catholic University of the Sacred Heart, Roma, Italy, ⁶Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷University of California San Diego, La Jolla, CA, ⁸Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Synovial membrane represents the target tissue of Rheumatoid Arthritis (RA) inflammation. Our study aimed to perform a comprehensive quantification of oxylipins and their precursors…
Abstract Number: 0417 • ACR Convergence 2023
The Role of Rheumatoid Arthritis Flare in the Risk of Alzheimer’s Disease and Related Dementias: A Population-based Cohort Study
Chanakya Kodishala¹, Tina Gunderson², Edward Lovering², Rakesh Kumar², Cynthia Crowson², John Davis² and Elena Myasoedova², ¹Mayo Clinic Rochester Minnesota, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased risk for Alzheimer's disease and related dementias (AD/ADRD). Recent studies have reported an association between RA disease…
Abstract Number: 0434 • ACR Convergence 2023
Effects of B/tsDMARDs on Non-inflammatory Pain in Patients with Rheumatoid Arthritis -ANSWER Longitudinal Cohort Study-
Mai Yamashita¹, Takaichi Okano¹, Iku Shirasugi¹, Hirotaka Yamada¹, Keisuke Nishimura¹, Sho Sendo¹, Yo Ueda¹, Toshihisa Maeda², Shinya Hayashi², Wataru Yamamoto³, Akira Onishi⁴, Kosaku Murakami⁵, Hideyuki Shiba⁶, Kenichiro Hata⁶, Kohei Tsujimoto⁷, Kosuke Ebina⁸, Yonsu Son⁹, Naofumi Yoshida⁹, Ryota Hara¹⁰, Ryu Watanabe¹¹, Motomu Hashimoto¹¹, Ryosuke Kuroda² and Jun Saegusa¹, ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan, ⁴Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Department of Internal Medicine (Ⅳ), Osaka Medical and Pharmaceutical University, Takatsuki, Japan, ⁷Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Toyonaka, Osaka, Japan, ⁸Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, Toyonaka,Osaka, Japan, ⁹First Department of Internal Medicine, Kansai Medical University, Osaka, Hirakata, Japan, ¹⁰Department of Orthopaedic Surgery, Nara Medical University, Nara, Japan, ¹¹Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Background/Purpose: Non-inflammatory pain (NIP) is one of the remaining issues in rheumatoid arthritis (RA), and some previous studies suggest that 10-20% of patients with RA…
Abstract Number: 0451 • ACR Convergence 2023
Long-term Clinical Profile of Filgotinib in Patients with Rheumatoid Arthritis by Cardiovascular Risk Factors: A Post Hoc Subgroup Analysis
Maya Buch¹, Jose A Gomez-Puerta², Gerd Burmester³, Bernard G. Combe⁴, Vijay Rajendran⁵, Pieter-Jan Stiers⁶, Paul Van Hoek⁷, Katrien Van Beneden⁷, Jacques-Eric Gottenberg⁸, Yoshiya Tanaka⁹, Daniel Aletaha¹⁰, René Westhovens¹¹ and Roberto F. Caporali¹², ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, ³Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ⁴Department of Rheumatology, Montpellier University, Montpellier, France, ⁵Clinical Research, Galapagos NV, Mechelen, Belgium, ⁶Biostatistics, Galapagos NV, Mechelen, Belgium, ⁷Medical Safety, Galapagos NV, Mechelen, Belgium, ⁸Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ⁹University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, ¹¹Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ¹²Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy
Background/Purpose: Filgotinib (FIL) is an oral Janus kinase 1 preferential inhibitor for the treatment of moderate to severe active RA. A previous pooled analysis reported…
Abstract Number: 0636 • ACR Convergence 2023
Chasing Pain: Investigating Somatosensory Profiles in Patients with Rheumatological Diseases Using Quantitative Sensory Testing
Claus Juergen Bauer¹, Ruth Sophie Schrapper², Simon Petzinna³, Charlotte Behning⁴, Tim T.A. Bender⁵, Peter Brossart¹, Martin Muecke⁶ and Valentin Sebastian Schäfer¹, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ²University of Bonn, Bonn, Germany, ³Clinic of Internal Medicine III, Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany, ⁴Institute of Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, Bonn, Germany, ⁵University Hospital of Bonn, Bonn, Germany, ⁶Universital Hospital of Aachen, Aachen, Germany
Background/Purpose: Pain is a prominent symptom in numerous rheumatological diseases. In order to allow for a standardized quantification and the assessment of nociceptive and non-nociceptive…
Abstract Number: 0793 • ACR Convergence 2023
The Dual Specificity Phosphatase 6 (DUSP6) Regulates Arthritis Severity and IL10 Production
Teresina Laragione, Carolyn Harris, Natasha Rice and Percio Gulko, Icahn school of Medicine at Mount Sinai, New York, NY
Background/Purpose: We have previously identified the Huntingtin-interacting protein-1 (HIP1) as a new gene implicated in the regulation of the rheumatoid arthritis (RA) fibroblast-like synoviocyte (FLS)…
Abstract Number: 0838 • ACR Convergence 2023
Infusion of Etanercept into the Peripheral Lymphatics Significantly Reduces Disease Activity in Rheumatoid Arthritis Patients with Inadequate Response to Subcutaneous Injections
Russell Ross¹, Vibeke Strand², Roel Querubin³, John Goldman⁴, Richard Leff⁵, Alexis Melson¹, Pei-Ling Roerig⁶ and Alan Smith⁷, ¹Sorrento Therapeutics, Atlanta, GA, ²Stanford University, Portola Valley, CA, ³Marietta Rheumatology Associates, Marietta, GA, ⁴Northside Hospital, Atlanta, GA, ⁵Kezar Life Sciences, Chadds Ford, PA, ⁶4P Therapeutics, Orlando, FL, ⁷4P Therapeutics, Atlanta, GA
Background/Purpose: The lymphatic system serves as a conduit for transporting immune cells and inflammatory molecules present in arthritic joints to lymph nodes (LN), playing a…
Abstract Number: 0986 • ACR Convergence 2023
Medication Use Patterns and Factors Associated with Abnormal Pregnancy Outcomes in Patients with Rheumatoid Arthritis in Korea
Yeo-Jin Song¹, Soo-Kyung Cho¹, Yu-Seon Jung², Jihyun Keum³, Sun-Young Jung², Dae Hyun Yoo⁴ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²College of Pharmacy, Chung-Ang University, Seoul, South Korea, ³Department of Obstetrics and Gynecology, College of Medicine, Hanyang University, Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: As female patients constitute a significant proportion of rheumatoid arthritis (RA) cases, pregnancy management is crucial for women with RA. This study aimed to…
Abstract Number: 1048 • ACR Convergence 2023
The Prediction of Response to Advanced Therapies on a Joint Level in Rheumatoid Arthritis: The Interpretation of Tenderness and Doppler Ultrasound
Seyyid Bilal Acikgoz¹, Ummugulsum Gazel², Ricardo Sabido-Sauri², Ozun Bayindir Tsechelidis³, Amin Zahrai⁴, Catherine Ivory⁴, Elliot Hepworth² and sibel aydin⁵, ¹University of Ottawa, Rheumatology, Ottawa, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: Ultrasound (US) has emerged as a sensitive method, especially when compared to clinical examination, for evaluating disease activity in Rheumatoid Arthritis (RA). Several studies…
Abstract Number: 1268 • ACR Convergence 2023
Clinical Characteristics of Patients with Rheumatoid Arthritis (RA) Who Rate Their Global Assessment of Disease Activity Substantially Lower Than Their Physicians (Negative Discordance) Based on a Large RA Database in Japan: A Rare but Important Subgroup
Tetsuji Sawada¹, Susumu Nishiyama², Shohei Yamashita³, Toshihiro Matsui⁴ and Shigeto Tohma⁵, ¹Tokyo Medical University Hospital, Shinjuku Tokyo, Japan, ²Kurashiki Medical Center, Kurashiki, Japan, ³Tokyo Medical University Hospital, Shinjuku, Japan, ⁴NHO Sagamihara National Hospital, Kanagawa, Japan, ⁵NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: Discordance between patient global assessment (PGA) and physician global assessment (PhGA) regarding the disease activity of rheumatoid arthritis (RA) can be divided into three…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].